{"name":"Lipocine Inc.","slug":"lipocine-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1976677,"revenueGrowth":-82.3,"grossMargin":0,"rdSpend":8583919,"netIncome":-9627505,"cash":17005612,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"LPCN 1154A","genericName":"LPCN 1154A","slug":"lpcn-1154a","indication":"Testosterone replacement therapy in hypogonadal men","status":"phase_3"},{"name":"Topical testosterone gel 1.62 %","genericName":"Topical testosterone gel 1.62 %","slug":"topical-testosterone-gel-1-62","indication":"Treatment of hypogonadism in adult males","status":"phase_3"},{"name":"LPCN 1021","genericName":"LPCN 1021","slug":"lpcn-1021","indication":"Testosterone replacement therapy in hypogonadal men","status":"phase_3"},{"name":"LPCN 1144 Formulation B","genericName":"LPCN 1144 Formulation B","slug":"lpcn-1144-formulation-b","indication":"Treatment of hypogonadism in men","status":"phase_2"},{"name":"Oral testosterone undecanoate, LPCN 1021","genericName":"Oral testosterone undecanoate, LPCN 1021","slug":"oral-testosterone-undecanoate-lpcn-1021","indication":"Testosterone replacement therapy in adult males with hypogonadism","status":"phase_3"}]}],"pipeline":[{"name":"LPCN 1154A","genericName":"LPCN 1154A","slug":"lpcn-1154a","phase":"phase_3","mechanism":"LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues.","indications":["Testosterone replacement therapy in hypogonadal men"],"catalyst":""},{"name":"Topical testosterone gel 1.62 %","genericName":"Topical testosterone gel 1.62 %","slug":"topical-testosterone-gel-1-62","phase":"phase_3","mechanism":"Topical testosterone gel 1.62% works by delivering testosterone through the skin to increase androgen levels in the body.","indications":["Treatment of hypogonadism in adult males"],"catalyst":""},{"name":"LPCN 1021","genericName":"LPCN 1021","slug":"lpcn-1021","phase":"phase_3","mechanism":"LPCN 1021 is a novel oral androgen receptor agonist designed to deliver testosterone systemically for hormone replacement therapy.","indications":["Testosterone replacement therapy in hypogonadal men"],"catalyst":""},{"name":"LPCN 1144 Formulation B","genericName":"LPCN 1144 Formulation B","slug":"lpcn-1144-formulation-b","phase":"phase_2","mechanism":"LPCN 1144 Formulation B is a testosterone replacement therapy.","indications":["Treatment of hypogonadism in men"],"catalyst":""},{"name":"Oral testosterone undecanoate, LPCN 1021","genericName":"Oral testosterone undecanoate, LPCN 1021","slug":"oral-testosterone-undecanoate-lpcn-1021","phase":"phase_3","mechanism":"Oral testosterone undecanoate replaces deficient testosterone by providing exogenous androgen that binds to androgen receptors throughout the body.","indications":["Testosterone replacement therapy in adult males with hypogonadism"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNRHpuMUdBblZLWmp2Zkd1ZVlrd3BPNHUtajYwamdUbXRZV2VVa3paVDJIdUVwQVVKR3pIenpaVmE2a2RrNGNtMzYxSEF6X2kwQTJSQktLd3VqVGsyTUxrUnhaaTZIbEY2Z3ZWb0Y2dlJkNndXTnZXQUJxeGIwZHl0LVFsbFp5cHpzM2lCREY0eGRvbGxIZTU5WTEwdkphb1BJYkRxLTE1OXIzVmVmalA1eXJya0g?oc=5","date":"2026-04-06","type":"pipeline","source":"BioCentury","summary":"Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - BioCentury","headline":"Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPZlNrc193Qzh1djIzY3dPcVEzaEE3bndOYnIwY3ZINk1SRmVGZXEtYWU2MmE4XzNqYWQ1Q00tb1RKVm9IQzdNVlNjdjNUanlCdmdRRjVaaXFGa2ItUjBGcDhyRFVFTnltRWFPYlg3VUVhLXZ5ZUl2Zno4Y1l1bjJkN2xoVWUxcWtQNGFfaE5NWGZwb2hudmpPS25DOXY?oc=5","date":"2026-04-03","type":"pipeline","source":"Sahm","summary":"Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm","headline":"Nasdaq Down 1%; US Initial Jobless Claims Fall","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNWTFMMTlnUm5pVm1HdW1Wd3NMUHJHWEdLZmRwbGo5VDRQaDNfSWtUY1FUQVh1RGZxNjNuZHdfX0FrOGZPTHgwbFJIS2RsZG9SSHFneTBZWlJQdEd5YkhILXd4X3U2NWdyQnEwVGJIZ2ZyZG1xTUlsRVlfbjBGSk1FT0p5OW1FQy13TkNESHZtZ25QbDhKM3Q4YWNNN3hOeEdYU2VzUnpIWWszeGVERjl4OA?oc=5","date":"2026-04-03","type":"earnings","source":"Sahm","summary":"Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm","headline":"Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQc0w1N2w1YmZQd2tLWGljYjJFV2lva25kajJEVFU2bVB5QmVDTmw1d042Y0NzOUxCUWZWdFNYWjFOR1dJUEUyRkpWTm1wbHJBLUNVdFNpd1dOanZHcHpIa0tCLUpfYUNJZEVFc01YTTBRWm1VV3dIdXpDdTlDOFFNbGNBOXEtY2xMeXNaM05fOWJOam5ZLU40RktBb1ZRMVRIWllYLVE3ZDZNVExuMm93NUVZZjU?oc=5","date":"2026-04-02","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga","headline":"12 Health Care Stocks Moving In Thursday's Intraday Session","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9tSFNwU3ZhR2t5amI2TDFkQVhjZjh1ZU9WdnNXM0JzSHJqWXFBaUpRSVItVzhGQ0pWRmhwWnVIMmUxNURkVUV6aXp4NWhxcXpjNDZkVnNxTElWVXVmQ1HSAWNBVV95cUxNRVBFYm84RFc2dWxvanFLRHJadldFOHdwNDY3Skw2S1ZXdlplSlZlV3VNaTUtaWl0c3JXVEZKRkRjUGgyTkw5NlgyMk9CTTl6cGJWNndJaTlFV2tBM0FIY01xSFU?oc=5","date":"2026-04-01","type":"pipeline","source":"Bitget","summary":"Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget","headline":"Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZlAxb3RJREVlaVJ0NXVsZUdfOTJrYTlxbm1jSnZQNGVEd0pwTGplYl9aZ0EwQ2lFS0plREl4TlhVVUFsU0ZMQ2E1b0xnOU1zc3lrVzZuSUpMV00wckpnZURvbUlNTjI5RWtYZUprRlotaHlpcWxKTHFBSXVZSmNhU0lIZEVZbG9MQUtSWlZxX0h5cC1JQ3VHSWttcDFNV2tuQURiWU1lTWY5c3A5R0RQQ2pvbVBHbUdi?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's After-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5xd01tSEI1VU9YUDl4V3ctVzBDYkZ2SURkOGl0S2Y3eG9BYTVTRXJjelhhenlyNzNneFA0a1JtWXBZMkVqNWFzSlA1bFIxY0JRNkkwUzhLc3RfaXFnb1huX3BEWFg0aFl3cHNCaUJB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Lipocine Inc (LPCN) - Stock Titan","headline":"If You Invested $1,000 in Lipocine Inc (LPCN)","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":4,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":1976677,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":1976677,"period":"2025-12-31"},{"value":11198144,"period":"2024-12-31"},{"value":11198144,"period":"2024-12-31"},{"value":-2850818,"period":"2023-12-31"},{"value":-2850818,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":8583919,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-9627505,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":17005612,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}